

# Terry E Goldberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3571361/publications.pdf>

Version: 2024-02-01

44  
papers

3,168  
citations

331670

21  
h-index

289244

40  
g-index

49  
all docs

49  
docs citations

49  
times ranked

4618  
citing authors

#	ARTICLE	IF	CITATIONS
1	Executive Subprocesses in Working Memory. Archives of General Psychiatry, 2003, 60, 889.	12.3	562
2	Further Evidence for Dementia of the Prefrontal Type in Schizophrenia?. Archives of General Psychiatry, 1987, 44, 1008.	12.3	493
3	Utility of Combinations of Biomarkers, Cognitive Markers, and Risk Factors to Predict Conversion From Mild Cognitive Impairment to Alzheimer Disease in Patients in the Alzheimer's Disease Neuroimaging Initiative. Archives of General Psychiatry, 2011, 68, 961.	12.3	293
4	Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research, 2008, 102, 108-115.	2.0	281
5	Association of Delirium With Long-term Cognitive Decline. JAMA Neurology, 2020, 77, 1373.	9.0	226
6	Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 103-111.	2.4	191
7	Cerebral blood flow measured by arterial spin labeling MRI at resting state in normal aging and Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2017, 72, 168-175.	6.1	142
8	Performance-Based Measures of Everyday Function in Mild Cognitive Impairment. American Journal of Psychiatry, 2010, 167, 845-853.	7.2	129
9	Verbal working memory dysfunction in schizophrenia: use of a Brown-Peterson paradigm. Psychiatry Research, 1995, 56, 155-161.	3.3	102
10	Neurobiology of cognitive aging: Insights from imaging genetics. Biological Psychology, 2008, 79, 9-22.	2.2	65
11	Extension and refinement of the predictive value of different classes of biomarkers in ADNI: Four-year follow-up data. Alzheimer's and Dementia, 2014, 10, 704-712.	0.8	59
12	Development and Cross-Validation of the UPSA Short Form for the Performance-Based Functional Assessment of Patients With Mild Cognitive Impairment and Alzheimer Disease. American Journal of Geriatric Psychiatry, 2011, 19, 915-922.	1.2	50
13	The Age-Related Perfusion Pattern Measured With Arterial Spin Labeling MRI in Healthy Subjects. Frontiers in Aging Neuroscience, 2018, 10, 214.	3.4	49
14	Antidepressants for cognitive impairment in schizophrenia â€” A systematic review and meta-analysis. Schizophrenia Research, 2014, 159, 385-394.	2.0	48
15	Association of APOE e2 genotype with Alzheimer's and non-Alzheimer's neurodegenerative pathologies. Nature Communications, 2020, 11, 4727.	12.8	46
16	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2015, 41, 1237-1247.	4.3	45
17	Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12017.	2.4	36
18	APOE Genotype Modulates Proton Magnetic Resonance Spectroscopy Metabolites in the Aging Brain. Biological Psychiatry, 2014, 75, 686-692.	1.3	31

#	ARTICLE	IF	CITATIONS
19	High-impact rare genetic variants in severe schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29
20	Levels of processing effects on recognition memory in patients with schizophrenia. <i>Schizophrenia Research</i> , 2005, 74, 101-110.	2.0	28
21	Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias. <i>JAMA Psychiatry</i> , 2022, 79, 359.	11.0	26
22	Cognitive training and neuroplasticity in mild cognitive impairment (COG-IT): protocol for a two-site, blinded, randomised, controlled treatment trial. <i>BMJ Open</i> , 2019, 9, e028536.	1.9	25
23	Breadth and depth of working memory and executive function compromises in mild cognitive impairment and their relationships to frontal lobe morphometry and functional competence. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 170-179.	2.4	24
24	Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 37-45.	3.7	23
25	Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 39, 165-173.	3.1	21
26	Intact global cognitive and olfactory ability predicts lack of transition to dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 326-334.	0.8	21
27	Advancing Computerized Cognitive Training for MCI and Alzheimer's Disease in a Pandemic and Post-pandemic World. <i>Frontiers in Psychiatry</i> , 2020, 11, 557571.	2.6	18
28	Effects of restriction of activities and social isolation on risk of dementia in the community. <i>International Psychogeriatrics</i> , 2021, 33, 1207-1215.	1.0	13
29	Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1085-1097.	2.6	12
30	Apolipoprotein E Genotype e2: Neuroprotection and Its Limits. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	12
31	Cortical Transcriptional Profiles in APOE4 Carriers with Alzheimer's Disease: Patterns of Protection and Degeneration. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 969-978.	2.6	10
32	Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time. <i>PLoS ONE</i> , 2020, 15, e0228064.	2.5	9
33	Associations of APOE e2 genotype with cerebrovascular pathology: a postmortem study of 1275 brains. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 7-11.	1.9	9
34	Differential medial temporal lobe morphometric predictors of item- and relational- encoded memories in healthy individuals and in individuals with mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 238-246.	3.7	8
35	The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1567-1580.	2.6	7
36	Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer's Disease Spectrum. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 30-39.	0.1	6

#	ARTICLE	IF	CITATIONS
37	Validity of the Web-Based, Self-Directed, NeuroCognitive Performance Test in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1131-1136.	2.6	5
38	Development of novel measures for Alzheimer's disease prevention trials (NoMAD). <i>Contemporary Clinical Trials</i> , 2021, 106, 106425.	1.8	4
39	Novel approaches to measuring neurocognitive functions in Alzheimer's disease clinical trials. <i>Current Opinion in Neurology</i> , 2022, 35, 240-248.	3.6	3
40	Comments about SuperAging and SuperAgers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 564-565.	2.4	2
41	A machine learning approach to identifying delirium from electronic health records. <i>JAMIA Open</i> , 2022, 5, .	2.0	2
42	Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer's disease trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12024.	2.4	1
43	Reply to: The Impact of Magnetic Resonance Spectroscopy in Elucidating the Role of Apolipoprotein E Epsilon4 in Preclinical Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, e41-e42.	1.3	0
44	DTA0106: ASSOCIATION OF APOE E2 GENOTYPE WITH NEUROPROTECTION: A TRANSDIAGNOSTIC STUDY OF 1557 BRAINS IN THE NACC V 10 DATA BASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1487.	0.8	0